ClinicalTrials.Veeva

Menu

Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)

C

Central Hospital, Nancy, France

Status

Unknown

Conditions

Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU

Treatments

Behavioral: Sensitivity and specificity of risk factors for degeneration of IPMNs

Study type

Observational

Funder types

Other

Identifiers

NCT04901364
2021PI064

Details and patient eligibility

About

Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis.

IPMNs require characterization to clarify their potential for degeneration. Clinical and morphological risk factors for degeneration determine the monitoring rate and the indication for pancreatic surgery.

Pancreatic surgery remains invasive with high morbidity and mortality rates.

Full description

This is a monoservice and monocentric retrospective study at the Nancy CHRU. We will study the risk factors for IPMNs degeneration in order to determine the most sensitive and specific.

To do this, we will use high-grade dysplasia or invasive cancer on the histological analysis of surgical specimens as the primary endpoint.

The study population will be patients with Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021.

Enrollment

57 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021, adults and without legal protection measures

Exclusion criteria

  • IPMNs not operated
  • Pancreatic cancer without IPMNs
  • Patients whose state of health contraindicates pancreatic surgery
  • Non-adult patient
  • Patients under legal protection

Trial contacts and locations

1

Loading...

Central trial contact

Marion MS SCHAEFER; Remy RF FONTANIE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems